Clinical and endoscopic study in patients who have peptic gastroduodenal ulcer, 1 year after the eradication from Helicobacter pylori. Valuation of the relationship between the appearence of erosive esophagitis and the strains from the eradicated Helicobacter pylori

Nowadays, there are many directrixes in literature as to the influence of Helicobacter pylori, in the Disease of Gastroesophagic reflux. Some authors believe that H. pylori could have a protective effect to the development of GERD, and others even conclude that the agent may be an aggravating factor in the disease. Many publications allert us to the development of symptoms of GERD, or even the esophagitis,in a reasonable percentage of erradicated patients by the triplicit scheme to treat H. pylori, and 10%, approximately, would have GERD. In fact, due to these doubts, a consensus has not been established yet to the importance of H. pylori in the GERDs etiopathogenic and its complications. The strains importance to the formation of esophagitis in patients submitted to erradication is another fact that has also been discussed. Maybe the most virulent ones, as the presence of pathogenical island(cagA) or some other vacuolating cytotoxin (vacA), would have a larger relation in the esophagitis prevention. Another important mechanism, pointed by many, to the formation of esophagitis in erradicated patients would be the elevation of Body Mass Index in this group of eradicated patients associated or not to the presence of hiatal hernia and justified by a better quality of life due to symptoms improvement after erradication. In our studies, 148 patients with active or healed peptic ulcer received triplicit scheme of erradication to the Helicobacter pylori and were submitted to endoscopic exams and histopathologic test of gathered samples by body and antro biopsies, respiratory test with carbon 14 and ureasis, before and after treatment. We have done the agent genotyping, through the PCR, separating samples of body and antro, to determine the agent Cepas. The patients have been followed ambulatorially for a year and evaluated as to the improvement or worsening of the symptoms related to GERD (pyrosis) and symptoms considered non-specific as epigastric pain; we have also tried to quantify the gain or loss of Body Mass Index. We found 28 patients(18.9%) with endoscopic erosive esophagitis (24 degree A and 4 degree B of Los Angeles) after agents treatment. In this group, only three patients who had no symptoms developed pyrosis (2%). Most of the patients benefitted from treatment showing that 69 (46.6%) presented improvement in pyrosis and another great majority improved non-specific symptoms. In 18 ulcered patients with esophagitis, the body analysis fragments was positive cagA (64.3%)and in antro samples of 21 were positive cagA (75%). As in the general group, the vacuolizing cepas slb/ml and slb were, respectivelly, the most found in the endoscopic esophagitis group. There was a slight raise in the BMI in patients with and without esophagitis, and it is, statistically more meaningful in the 120 patients without esophagitis. Even though there was the appearance of endoscopic erosive esophagitis in a reasonable number of patients, the symptmology was not a determining factor, because many have got better after the treatment, and erradication was not important to determine the erosive esophagitis. It was not found any relation between the agent genotyping and the development of endoscopic esophagitis. The raise of BMI does not justify in our study the esophagitis in ulcered patients treated against H. pylori.

WARNING - Viewing this document is conditioned on your acceptance of the following terms of use:This document is only for private use for research and teaching activities. Reproduction for commercial use is forbidden. This rights cover the whole data about this document as well as its contents. Any uses or copies of this document in whole or in part must include the author's name.